Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM-101 in Systemic Sclerosis
NCT06210945Phase 2Suspended
- Sponsor
- Chemomab Therapeutics
- Start
- Sep 2026
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nebokitug in systemic sclerosis (SSc), sponsored by Chemomab Therapeutics. Started Sep 2026; status: suspended.
02
Drugs
nebokitug
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT06210945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06210945.